Immutep Ltd Share Price Australian S.E.
Equities
AU000000PRR9
Biotechnology & Medical Research
Sales 2024 * | 3.11M 2.06M 163M | Sales 2025 * | 4.57M 3.03M 240M | Capitalization | 477M 316M 25.04B |
---|---|---|---|---|---|
Net income 2024 * | -46M -30.47M -2.41B | Net income 2025 * | -56M -37.1M -2.94B | EV / Sales 2024 * | 104 x |
Net cash position 2024 * | 154M 102M 8.07B | Net cash position 2025 * | 105M 69.33M 5.49B | EV / Sales 2025 * | 81.5 x |
P/E ratio 2024 * |
-9.11
x | P/E ratio 2025 * |
-7.9
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.92% |
Managers | Title | Age | Since |
---|---|---|---|
Marc Voigt
CEO | Chief Executive Officer | 51 | 31/12/10 |
David Fang
DFI | Director of Finance/CFO | - | 28/02/18 |
Florian Vogl
CTO | Chief Tech/Sci/R&D Officer | - | 30/04/23 |
Members of the board | Title | Age | Since |
---|---|---|---|
Russell Howard
CHM | Chairman | 74 | 07/05/13 |
Marc Voigt
CEO | Chief Executive Officer | 51 | 31/12/10 |
Anne Anderson
BRD | Director/Board Member | - | 02-13 |
1st Jan change | Capi. | |
---|---|---|
+21.85% | 46.93B | |
+37.63% | 39.08B | |
-8.05% | 38.48B | |
+29.04% | 31.01B | |
-13.75% | 26.14B | |
+10.65% | 25.88B | |
+38.43% | 12.53B | |
-6.92% | 11.36B | |
-12.29% | 10.65B |